These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6304787)

  • 21. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram.
    Souness JE; Maslen C; Webber S; Foster M; Raeburn D; Palfreyman MN; Ashton MJ; Karlsson JA
    Br J Pharmacol; 1995 May; 115(1):39-46. PubMed ID: 7647982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.
    Turner NC; Lamb J; Worby A; Murray KJ
    Br J Pharmacol; 1994 Apr; 111(4):1047-52. PubMed ID: 8032589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacodynamic action of the cyclic AMP phosphodiesterase inhibitor rolipram on prolactin producing rat pituitary adenoma (GH4C1) cells.
    Gordeladze JO
    Biosci Rep; 1990 Aug; 10(4):375-88. PubMed ID: 2174276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.
    O'Donnell JM; Frith S
    Pharmacol Biochem Behav; 1999 May; 63(1):185-92. PubMed ID: 10340540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva.
    Newsholme SJ; Schwartz L
    Inflammation; 1993 Feb; 17(1):25-31. PubMed ID: 8381769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesterase.
    Stafford JA; Veal JM; Feldman PL; Valvano NL; Baer PG; Brackeen MF; Brawley ES; Connolly KM; Domanico PL; Han B
    J Med Chem; 1995 Dec; 38(26):4972-5. PubMed ID: 8544172
    [No Abstract]   [Full Text] [Related]  

  • 27. The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration.
    Knapp CM; Foye MM; Ciraulo DA; Kornetsky C
    Pharmacol Biochem Behav; 1999 Jan; 62(1):151-8. PubMed ID: 9972858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
    Makhay MM; Houslay MD; O'Donnell JM
    Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K; Burke-Gaffney A; Hellewell PG
    Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of rolipram, a selective inhibitor of phosphodiesterase 4, on hyperlocomotion induced by several abused drugs in mice.
    Mori T; Baba J; Ichimaru Y; Suzuki T
    Jpn J Pharmacol; 2000 Jun; 83(2):113-8. PubMed ID: 10928323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
    Bacher E; Boer C; Bray-French K; Demnitz FW; Keller TH; Mazzoni L; Müller T; Walker C
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3229-34. PubMed ID: 9873708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purification, characterization and analysis of rolipram inhibition of a human type-IVA cyclic AMP-specific phosphodiesterase expressed in yeast.
    Wilson M; Sullivan M; Brown N; Houslay MD
    Biochem J; 1994 Dec; 304 ( Pt 2)(Pt 2):407-15. PubMed ID: 7528009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin.
    Teixeira MM; Miotla JM; Cooper N; Gristwood RW; Hellewell PG
    Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():193-6. PubMed ID: 9698932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.
    MacKenzie SJ; Houslay MD
    Biochem J; 2000 Apr; 347(Pt 2):571-8. PubMed ID: 10749688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors.
    Wachtel H
    Psychopharmacology (Berl); 1982; 77(4):309-16. PubMed ID: 6182575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 37. Modulation of cellular responses by hormones: role of cAMP specific, rolipram-sensitive phosphodiesterases.
    Sette C; Vicini E; Conti M
    Mol Cell Endocrinol; 1994 Apr; 100(1-2):75-9. PubMed ID: 8056162
    [No Abstract]   [Full Text] [Related]  

  • 38. Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.
    Faisy C; Risse PA; Naline E; Guerot E; Fagon JY; Devillier P; Advenier C
    Life Sci; 2006 Oct; 79(20):1929-35. PubMed ID: 16820175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective inhibition of one of the cyclic AMP phosphodiesterases from rat brain by the neurotropic compound rolipram.
    Nemoz G; Prigent AF; Moueqqit M; Fougier S; Macovschi O; Pacheco H
    Biochem Pharmacol; 1985 Aug; 34(16):2997-3000. PubMed ID: 2992527
    [No Abstract]   [Full Text] [Related]  

  • 40. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.